Intra-Cellular Therapies Inc (NASDAQ:ITCI) shares were up 8.2% during mid-day trading on Wednesday . The company traded as high as $19.43 and last traded at $19.19. Approximately 599,959 shares were traded during mid-day trading, an increase of 37% from the average daily volume of 437,486 shares. The stock had previously closed at $17.73.

A number of research analysts have issued reports on ITCI shares. Zacks Investment Research downgraded Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a report on Tuesday, January 23rd. ValuEngine downgraded Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research note on Tuesday, December 5th. BidaskClub downgraded Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research note on Tuesday, December 12th. Finally, Canaccord Genuity initiated coverage on Intra-Cellular Therapies in a research note on Friday, December 15th. They set a “buy” rating and a $31.00 target price for the company. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $26.70.

The company has a market cap of $924.00, a P/E ratio of -8.06 and a beta of 0.86.

In related news, CFO Lawrence J. Hineline sold 3,192 shares of the stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $15.67, for a total value of $50,018.64. Following the completion of the transaction, the chief financial officer now directly owns 68,686 shares of the company’s stock, valued at approximately $1,076,309.62. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Richard A. Lerner sold 7,000 shares of the stock in a transaction on Monday, December 11th. The shares were sold at an average price of $15.09, for a total value of $105,630.00. Following the completion of the transaction, the director now directly owns 8,621 shares of the company’s stock, valued at $130,090.89. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 56,160 shares of company stock valued at $966,934. Corporate insiders own 21.00% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. acquired a new position in Intra-Cellular Therapies in the 3rd quarter valued at $101,000. Quantbot Technologies LP raised its stake in Intra-Cellular Therapies by 233.1% in the 3rd quarter. Quantbot Technologies LP now owns 8,614 shares of the biopharmaceutical company’s stock valued at $135,000 after purchasing an additional 6,028 shares during the last quarter. SG Americas Securities LLC raised its stake in Intra-Cellular Therapies by 45.9% in the 3rd quarter. SG Americas Securities LLC now owns 12,060 shares of the biopharmaceutical company’s stock valued at $190,000 after purchasing an additional 3,794 shares during the last quarter. Voya Investment Management LLC raised its stake in Intra-Cellular Therapies by 16.0% in the 2nd quarter. Voya Investment Management LLC now owns 16,911 shares of the biopharmaceutical company’s stock valued at $210,000 after purchasing an additional 2,338 shares during the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in Intra-Cellular Therapies in the 4th quarter valued at $212,000. 74.77% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Intra-Cellular Therapies (ITCI) Trading Up 8.2%” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.watchlistnews.com/intra-cellular-therapies-itci-trading-up-8-2/1866518.html.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.